Bacteriophage Therapy: Retrospective Review and Future Prospects

TIAN Er-kang, WANG Yue, WU Zhuo-xuan, WAN Zi-qian-hong, CHENG Wei

Abstract

At present, bacterial infections are mainly treated with antibiotics, but new treatment methods are urgently needed because of growing problems with antibiotic resistance. Therefore, phage therapy will be a potential solution to the problem of bacterial drug resistance, and the combined use of bacteriophage and antibiotics is also considered a potential treatment option. However, there has not been any well-designed clinical controlled trials on phage therapy. More future research needs to be done to solve the problems of phage therapy, for example, its narrow antibacterial spectrum, the uncertainty regarding treatment safety, and the bacterial resistance. Some refractory diseases such as breast cancer and alcoholic hepatitis are difficult to treat clinically. The successful experimental research on bacteriophages reported in these fields provides new ideas of treatment for more refractory diseases in the future. In addition, bacteriophages also showed promising performance in vaccine applications and osteanagenesis. We herein summarize the existing weaknesses of phage therapy and its application prospects in treating systemic diseases, hoping to promote further clinical application research of phage therapy.

 

Keywords: Phage therapy, Multidrug resistance, Systemic disease

 

Full Text:

PDF


References


JEON G， AHN J. Assessment of phage-mediated inhibition of Salmonella Typhimurium treated with sublethal concentrations of ceftriaxone and ciprofloxacin. FEMS Microbiol Lett，2020，367(19): 19.

ŁUSIAK-SZELACHOWSKA M， MIĘDZYBRODZKI R， FORTUNA W， et al. Anti-phage serum antibody responses and the outcome of phage therapy. Folia Microbiol (Praha)，2021，66(1): 127–131.

HESSE S， ADHYA S. Phage therapy in the twenty-first century: facing the decline of the antibiotic era; is it finally time for the age of the phage?Annu Rev Microbiol，2019，73: 155–174.

SUNDERLAND K S， YANG M， MAO C. Phage-enabled nanomedicine: from probes to therapeutics in precision medicine. Angew Chem Int Ed Engl，2017，56(8): 1964–1992.

CHATTERJEE S， ROTHENBERG E. Interaction of bacteriophage l with its E. coli receptor, LamB. Viruses，2012，4(11): 3162–3178.

HERMOSO J， GARCíA J， GARCíA P. Taking aim on bacterial pathogens: from phage therapy to enzybiotics. Curr Opin Microbiol，2007，10(5): 461–472.

CHANG R Y K， WALLIN M， LIN Y， et al. Phage therapy for respiratory infections. Adv Drug Deliv Rev，2018，133: 76–86.

GOLSHAHI L， SEED K D， DENNIS J J， et al. Toward modern inhalational bacteriophage therapy: nebulization of bacteriophages of Burkholderia cepacia complex. J Aerosol Med Pulm Drug Deliv，2008， 21(4): 351–360.

YANG H， MA Y， WANG Y， et al. Transcription regulation mechanisms of bacteriophages: recent advances and future prospects. Bioengineered， 2014，5(5): 300–304.

MAXWELL K L. Phages tune in to host cell quorum sensing. Cell，2019， 176(1/2): 7–8.

TAATI MOGHADAM M， AMIRMOZAFARI N， SHARIATI A， et al. How phages overcome the challenges of drug resistant bacteria in clinical infections. Infect Drug Resist，2020，13: 45–61.

BERTOZZI SILVA J， STORMS Z， SAUVAGEAU D. Host receptors for bacteriophage adsorption. FEMS Microbiol Lett，2016，363(4): 2–11.

REYES-ROBLES T， DILLARD R， CAIRNS L， et al. Vibrio cholerae outer membrane vesicles inhibit bacteriophage infection. J Bacteriol， 2018， 200(15): e00792-17[2020-11-03]. http://jb.asm.org/content/200/ 15/e00792-17. doi: 10.1128/jb.00792-17.

ALSETH E O， PURSEY E， LUJÁN A M， et al. Bacterial biodiversity drives the evolution of CRISPR-based phage resistance. Nature，2019， 574(7779): 549–552.

AZAM A H， TANJI Y. Bacteriophage-host arm race: an update on the mechanism of phage resistance in bacteria and revenge of the phage with the perspective for phage therapy. Appl Microbiol Biotechnol，2019， 103(5): 2121–2131.

ABBINENI G， MODALI S， SAFIEJKO-MROCZKA B， et al. Evolutionary selection of new breast cancer cell-targeting peptides and phages with the cell-targeting peptides fully displayed on the major coat and their effects on actin dynamics during cell internalization. Mol Pharm，2010，7(5): 1629–1642.

DABROWSKA K， ZEMBALA M， BORATYNSKI J， et al. Hoc protein regulates the biological effects of T4 phage in mammals. Arch Microbiol， 2007，187(6): 489–498.

AN T， KIM S， LEE Y， et al. The immune-enhancing effect of the Cronobacter sakazakii ES2 phage results in the activation of nuclear factor-κB and dendritic cell maturation via the activation of IL-12p40 in the mouse bone marrow. Immunol Lett，2014，157: 1–8.

GORDILLO ALTAMIRANO F L， BARR J J. Phage therapy in the postantibiotic era. Clin Microbiol Rev， 2019， 32(2): e00066-18[2020-11-03]. http://cmr.asm.org/content/32/2/e00066-18. doi: 10.1128/cmr.0006

LI W， SCHÄFER A， KULKARNI S， et al. High potency of a bivalent human V domain in SARS-CoV-2 animal models. Cell，2020，183(2): 429–441. e16[2020-11-03]. https://doi.org/10.1016/j.cell.2020.09.007.

STEELE A， STACEY H J， DE SOIR S， et al. The safety and efficacy of phage therapy for superficial bacterial infections: a systematic review. Antibiotics (Basel)，2020，9(11): 754–768.

BROWN T L， PETROVSKI S， DYSON Z A， et al. The formulation of bacteriophage in a semi solid preparation for control of Propionibacterium acnes growth. PLoS One，2016，11(3): e0151184[2020-11-03]. https://doi. org/10.1371/journal.pone.0151184.

SHETTIGAR K， MURALI T S. Virulence factors and clonal diversity of Staphylococcus aureus in colonization and wound infection with emphasis on diabetic foot infection. Eur J Clin Microbiol Infect Dis，2020，39(12): 2235–2246.

KIFELEW L G， WARNER M S， MORALES S， et al. Efficacy of phage cocktail AB-SA01 therapy in diabetic mouse wound infections caused by multidrug-resistant Staphylococcus aureus. BMC Microbiol，2020，20(1): 204.

VAHEDI A， SOLTAN DALLAL M M， DOURAGHI M， et al. Isolation and identification of specific bacteriophage against enteropathogenic Escherichia coli (EPEC) and in vitro and in vivo characterization of bacteriophage. FEMS Microbiol Lett， 2018， 365(16): fny136[2020-11-03]. https://doi.org/10.1093/femsle/fny136.

DUERKOP B A， CLEMENTS C V， ROLLINS D， et al. A composite bacteriophage alters colonization by an intestinal commensal bacterium. Proc Natl Acad Sci U S A，2012，109(43): 17621–17626.

BROUDY T B， FISCHETTI V A. In vivo lysogenic conversion of Tox－Streptococcus pyogenes to Tox+ with lysogenic Streptococci or free phage. Infect Immun，2003，71(7): 3782–3786.

RHOADS D D， WOLCOTT R D， KUSKOWSKI M A， et al. Bacteriophage therapy of venous leg ulcers in humans: results of a phase Ⅰ safety trial. J Wound Care，2009，18(6): 237–243.

KHALIFA L， BROSH Y， GELMAN D， et al. Targeting Enterococcus faecalis biofilms with phage therapy. Appl Environ Microbiol，2015， 81(8): 2696–2705.

KHALIFA L， GELMAN D， SHLEZINGER M， et al. Defeating antibiotic- and phage-resistant Enterococcus faecalis using a phage cocktail in vitro and in a clot Model. Front Microbiol， 2018， 9: 326[2020-11-03]. https://doi.org/10.3389/fmicb.2018.00326.

TINOCO J M， BUTTARO B， ZHANG H， et al. Effect of a genetically engineered bacteriophage on Enterococcus faecalis biofilms. Arch Oral Biol，2016，71: 80–86.

DUNNE M， HUPFELD M， KLUMPP J， et al. Molecular basis of bacterial host interactions by Gram-positive targeting bacteriophages. Viruses， 2018， 10(8): 397[2020-11-03]. https://doi.org/10.3390/v 10080397.


Refbacks

  • There are currently no refbacks.